RankAlpha logo
Back to Rankings

ANTX

AN2 TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The bull case is that March financing extended runway into 2029, three Phase 2 programs are expected to be active in 2026, and the PV study offers the nearest company-controlled proof-of-concept catalyst with potential readouts beginning as early as 4Q26 [#IR-2026-03-17].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -8.4.
What can break
ATM usage or other equity issuance could pressure the stock despite improved runway [#8-K-2026-04-09].
Momentum
83
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.00 · Bull $7.50 · Bear $2.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum83 · Δ7d -8.4
Value41 · Δ7d +0.0
Sentiment34 · Δ7d +37.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
83
26% active weight
Current posture
7d trendSoftening
Δ7d
-8.4
Δ21d
-8.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
34
34% active weight
Current posture
7d trendImproving
Δ7d
+37.5
Δ21d
+37.5
Why this grade

Composite grade C. Momentum 83.3 / Value 41.1 / Sentiment 34.1

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$172.88M
Beta
-0.03
Shares Out
36.02M
P/E (TTM) · Derived
-4.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.85
Rev YoY
-
EPS YoY
-16.9%
Gross Margin
-
Op Margin
-
Net Debt
-$58M
Current Ratio
15.73
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology